research report      name index      key word index      corresp.unit            Page in german      Imprint + Privacy Policy   

Third-party-funded project

Title:
A trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis

Project management at the University of Würzburg:

• Prof. Dr. med. Klaus Toyka , Direktor der Neurologischen Universitätsklinik,Tel: 201-23751,Fax: 201-23697,Mail: k.toyka@mail.uni-wuerzburg.de
• Prof. Dr. med. Michael Sendtner ,Tel: 201-49767,Fax: 201-49788,Mail: sendtner@mail.uni-wuerzburg.de

Participating scientists:

• Prof. Dr. med. Günther Ochs
• Dr. med. Ralf Gieß
• Dr. med. Marcus Beck

Abstract:
BDNF is a potent survival factor for lesioned and degenerating motoneurons in the various animal models for human disease. We could show in a first phase 1/2 clinical study that intrathecal infusion of BDNF is well tolerated, and that BDNF is taken up by degenerating motoneurons and activates signalling pathways in these cells.

Key words:
    Clinical trial
    Brain-derived neurotrophic factor
    Motoneuron
    Amyotrophic lateral sclerosis

Projekt period: from 01.1999 to 12.2000

Funding institution:
DFG ( To 61/8-3 ) ,Granting date: 19.08.1996
Wirtschaftsunternehmen ( Amgen )

Preceding project:
8420135 DFG To 61/8-1

Publications:

• Ochs et al.. (2000). A trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis 2, (scientific article)

Links:
Institute for Clinical Neurobiology